Background and Methods. Philadelphia (Ph) positive chronic myeloid leu
kemia (CML) cannot be induced into a true remission with conventional
chemotherapy. Blast cells and precursors obtained from 51 Ph(+) CML ca
ses were assayed for expression of the multidrug resistance (MDR)assoc
iated glycoprotein (p170) by immunocytochemistry (APAAP) with the MRK-
16 monoclonal antibody. Results and Conclusions. Positive cells were f
ound in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerate
d phase, and in 23/26 cases in blastic phase (89%). The proportion of
positive cells, which ranged between less than 1% and 95%, was higher
in blastic phase (mean 32+/-29.9) than in chronic phase (mean 3+/-5.3)
(p = 0.006). These findings show that p170 overexpression is common i
n Ph(+) CML, especially after progression to blastic phase, and sugges
t that p170-related MDR may contribute significantly to treatment fail
ure.